Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation

Launched by M.D. ANDERSON CANCER CENTER · Dec 13, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how well patients with esophageal cancer respond to the pneumococcal vaccine after receiving radiation treatment. Specifically, it aims to understand how different types of radiation therapy, like proton therapy and intensity-modulated radiation therapy (IMRT), affect the immune system's ability to react to vaccines that protect against pneumonia, a serious lung infection.

To participate in this trial, you need to be an adult who is currently undergoing or has recently completed radiation treatment for esophageal cancer or certain types of liver cancer. Healthy individuals of similar age and gender are also welcome to join. Participants will provide information about their health and receive the pneumococcal vaccine, and researchers will monitor how their immune systems respond. It's important to note that individuals with certain health conditions or previous vaccinations may not be eligible. This study will help improve our understanding of vaccine effectiveness in patients who have undergone cancer treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Group 1A
• • a. Participants currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer with protons.
• • 2. Group 1B
• • a. Participants currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer with intensity-modulated radiation therapy (IMRT)
• • 3. Group 2A
• • a. Participants currently receiving, planning to receive, or recently completed definitive proton therapy for unresectable hepatocellular carcinoma.
• • 4. Group 2B
• • a. Participants currently receiving, planning to receive, or recently completed definitive IMRT for unresectable hepatocellular carcinoma.
• • 5. Group 3
• • a. Healthy age- and gender- matched individuals
• • 6. All Groups
• • 1. Participants of all genders, races and nationalities will be solicited.
• • 2. Age \>18 years
• • 3. Ability to understand and the willingness to sign a written informed consent document.
• Exclusion Criteria:
• • Participants with compromised immunologic responses due to an uncontrolled intercurrent immunodeficiency (e.g., Human immunodeficiency virus (HIV), X-linked agammaglobulinemia) or previous or current immune suppressive therapy
• • a. Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
• • Participants receiving intravenous immunoglobulin (IVIG) during the study or in the three months prior to study enrollment.
• • Participants with psychiatric illness/social situations that would limit compliance with study requirements.
• • Participants with previous pneumococcal vaccination
• • Participants with severe allergy to any of the vaccine components